Related Experiment Video
Updated: Nov 8, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound
V V Barchukov1, I B Tsorin1, M B Vititnova1
1V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
Abstract:
The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function (p=0.038). This effect was observed in case of systematic administration of ALM-802 over 28 days (starting from day 91 after infarction modeling). This is apparently the minimum time for the cardioprotective effect of ALM-802 to prevent or treat the resulting heart failure, because short-term systematic therapy (15 days) produced no positive effect.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy